Global access and quality of conservative kidney management
Most countries report some capacity for CKM. However, there is considerable variability in terms of how CKM is defined, as well as what and how much care is provided. Poor access to CKM perpetuates unmet palliative care needs, and must be addressed, particularly in low-resource settings where death from untreated kidney failure is common.
Authors
- Sandrine Damster
- Syed Saad
- Sara N. Davison (ORCID: https://orcid.org/0000-0003-4513-6449)
- Nicola Wearne (ORCID: https://orcid.org/0000-0001-9917-223X)
- Marcello Tonelli (ORCID: https://orcid.org/0000-0002-0846-3187)
- Masaomi Nangaku (ORCID: https://orcid.org/0000-0001-7401-2934)
- Vivekanand Jha (ORCID: https://orcid.org/0000-0002-8015-9470)
- Ikechi G. Okpechi (ORCID: https://orcid.org/0000-0002-6545-9715)
- Jo‐Ann Donner (ORCID: https://orcid.org/0000-0002-5005-909X)
- Barnaby Hole (ORCID: https://orcid.org/0000-0003-2414-1302)
- Fergus Caskey (ORCID: https://orcid.org/0000-0002-5199-3925)
- Silvia Arruebo
- Feng Ye (ORCID: https://orcid.org/0000-0001-6130-1817)
- Adeera Levin
- Aminu K. Bello (ORCID: https://orcid.org/0000-0001-5021-5542)
- David W Johnson
Institutions
- University of British Columbia (CA)
- University of Alberta (CA)
- University of Cape Town (ZA)
- The University of Queensland (AU)
- University of Calgary (CA)
- Princess Alexandra Hospital (AU)
- Groote Schuur Hospital (ZA)
- University of Bristol (GB)
- George Institute for Global Health (IN)
- The University of Tokyo (JP)
Publication Details
- Journal
- Nephrology Dialysis Transplantation
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1093/ndt/gfae129
- Citations
- 12
- Primary Topic
- Dialysis and Renal Disease Management
- Type
- article
- Field-Weighted Citation Impact
- 4.07
Funders
- Amgen
- Eli Lilly and Company
- AstraZeneca
- Heart and Stroke Foundation of Canada
- International Society of Nephrology
- BioCryst
- Fresenius Medical Care North America
- University of Alberta
- Astellas Pharma
- Akebia Therapeutics
- Chugai Pharmaceutical
- Medical Research Council
- Daiichi Sankyo Europe